Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04969926 · ClinicalTrials.gov registry record

Natural History Study of Parathyroid Disorders

A clinical trial of Primary Hyperparathyroidism and Pseudohypoparathyroidism, sponsored by National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK).

Recruiting
Registry status
3,000
Enrollment target
1
Study location

NCT04969926: Recruiting study of Primary Hyperparathyroidism and Pseudohypoparathyroidism, sponsored by National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK).

NCT04969926 is a study of Primary Hyperparathyroidism and Pseudohypoparathyroidism that is actively recruiting participants, run by National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK). The registered enrollment target is 3,000 participants, above the 323-participant average among 7 other Primary Hyperparathyroidism trials with a reported enrollment target (829% higher). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04969926, a study of Primary Hyperparathyroidism and Pseudohypoparathyroidism, is actively recruiting participants, sponsored by National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK).

RECRUITING
Registry status
3,000 participants
Enrollment target
1
Study location

Study Summary

Background: Parathyroid disorders are very common in the general population and include disorders of parathyroid excess, deficiency, or defects in parathyroid hormone (PTH) signaling. PTH, the main secretory product of parathyroid glands is responsible for regulation of calcium-phosphate homeostasis. Objective: i) To investigate the cause of parathyroid disorders ii) To describe evolution, natural history, and longitudinal trends of parathyroid and related disorders seen in syndromic presentations like multiple endocrine neoplasia, hyperparathyroidism-jaw tumor syndrome Eligibility: People ages 6 months older who have, are at risk of having, or are related to a person with a parathyroid or related disorder. Design: Participants will be screened with a review of their medical records. Participants will be seen, tested, and treated by doctors based on their condition. Their visits may be in person or via telehealth. Participants will complete questionnaires. They will answer questions about their physical, mental, and social health. Participants may give samples such as saliva, blood, urine, or stool. Participants may give cheek cell samples. They will do this using a cheek swab or by spitting into a cup. Adult participants may give a skin biopsy. For this, a small bit of skin is removed with a punch tool. Participants may have medical photos taken. If participants have surgery during the course of their regular care either at the NIH or at a different hospital or doctor s office, researchers will ask for some of the leftover tissue. Participants will be in the study as long as they are being seen by their doctor.

Primary Outcome

Participants will undergo standard clinical evaluations for their condition. Data obtained during these evaluations will be retained for purposes of the primary objective, for analysis of secondary objectives, and for future research. There are no mandatory study procedures for this protocol.

Study Locations (1)

Maryland

  • National Institutes of Health Clinical Center - Bethesda

Trial Details

FieldValue
Enrollment Target 3,000 participants
Start Date 2021-11-30
Est. Completion 2031-01-22

What NCT04969926 shows while recruiting

NCT04969926 is an observational study that tracks outcomes without assigning an intervention. Its 3,000 participants enrollment target places it among the larger protocols in the corpus, above the 323-participant average among 7 other Primary Hyperparathyroidism trials with a reported enrollment target (829% higher).

The record links to 5 conditions, with Primary Hyperparathyroidism appearing as the primary indexed condition, and to 0 interventions.

NCT04969926 reports a single indexed study location in Maryland.

Frequently Asked Questions

What is clinical trial NCT04969926 about?

NCT04969926 is a clinical study titled "Natural History Study of Parathyroid Disorders". Background: Parathyroid disorders are very common in the general population and include disorders of parathyroid excess, deficiency, or defects in parathyroid hormone (PTH) signaling. PTH, the main secretory product of parathyroid glands is responsible for regulation of calcium-phosphate homeostasi...

What is the current status of trial NCT04969926?

This trial is currently recruiting. The enrollment target is 3,000 participants. The study started on 2021-11-30. Estimated completion is 2031-01-22.

What conditions does trial NCT04969926 study?

This clinical trial studies the following conditions: Primary Hyperparathyroidism, Pseudohypoparathyroidism, Multiple Endocrine Neoplasia, Type 1, Parathyroid Cancer, Inheritable Bone Diseases.

Who is sponsoring clinical trial NCT04969926?

This trial is sponsored by National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), which has 490 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT04969926 being conducted?

This trial has 1 study location across Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Primary Hyperparathyroidism

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT00004847 · 3,000 participants · Phase 1

    Diagnosis of Pheochromocytoma

  • NCT00478712 · 3,000 participants

    Hirschsprung Disease Genetic Study

  • NCT00579566 · 3,000 participants

    Novel Biochemical and Molecular Determinants for Soft Tissue Sarcoma

  • NCT00816114 · 3,000 participants

    Chart Review Study of Chronic Myelogenous Leukemia (CML) Patients Treated With Imatinib Outside of a Clinical Trial

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT04969926, the US trial registry maintained by the National Library of Medicine. NCT04969926 (large enrollment · single site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.